JAMA
US Preventive Services Task Force
Modeling Study
April 30, 2024
Amy聽Trentham-Dietz,聽PhD, MS; Christina Hunter聽Chapman,聽MD, MS; Jinani聽Jayasekera,聽PhD, MS; Kathryn P.听Lowry,聽MD; Brandy M.听Heckman-Stoddard,聽PhD, MPH; John M.听Hampton,聽MS; Jennifer L.听Caswell-Jin,聽MD; Ronald E.听Gangnon,聽PhD; Ying聽Lu,聽PhD, MS; Hui聽Huang,聽MS; Sarah聽Stein,聽PhD; Liyang聽Sun,聽MS; Eugenio J.听Gil Quessep,聽MS; Yuanliang聽Yang,聽MS; Yifan聽Lu,聽BASc; Juhee聽Song,聽PhD; Diego F.听Mu帽oz,聽PhD; Yisheng聽Li,聽PhD, MS; Allison W.听Kurian,聽MD, MSc; Karla聽Kerlikowske,聽MD; Ellen S.听O鈥橫eara,聽PhD; Brian L.听Sprague,聽PhD; Anna N. A.听Tosteson,聽ScD; Eric J.听Feuer,聽PhD; Donald聽Berry,聽PhD; Sylvia K.听Plevritis,聽PhD; Xuelin聽Huang,聽PhD; Harry J.听de Koning,聽MD, PhD; Nicolien T.听van Ravesteyn,聽PhD; Sandra J.听Lee,聽ScD; Oguzhan聽Alagoz,聽PhD, MS; Clyde B.听Schechter,聽MD, MA; Natasha K.听Stout,聽PhD; Diana L.听Miglioretti,聽PhD, ScM; Jeanne S.听Mandelblatt,聽MD, MPH
free access
is active quiz
has multimedia
online first
JAMA. 2024; 10.1001/jama.2023.24766
This modeling study uses Cancer Intervention and Surveillance Modeling Network models and national data on breast cancer incidence, mammography performance, treatment effects, and other-cause mortality in US women without previous cancer diagnoses to estimate outcomes of various mammography screening strategies.
JAMA
Comment & Response
April 25, 2024
Jennifer L.听Caswell-Jin,聽MD; Allison W.听Kurian,聽MD, MSc; Sylvia K.听Plevritis,聽PhD
online first
JAMA. 2024; 10.1001/jama.2024.5482
JAMA
Original Investigation
January 16, 2024
Jennifer L.听Caswell-Jin,聽MD; Liyang P.听Sun,聽MSc; Diego聽Munoz,聽PhD; Ying聽Lu,聽PhD; Yisheng聽Li,聽PhD; Hui聽Huang,聽MS; John M.听Hampton,聽MSc; Juhee聽Song,聽PhD; Jinani聽Jayasekera,聽PhD; Clyde聽Schechter,聽MD, MA; Oguzhan聽Alagoz,聽PhD; Natasha K.听Stout,聽PhD; Amy聽Trentham-Dietz,聽PhD; Sandra J.听Lee,聽ScD; Xuelin聽Huang,聽PhD; Jeanne S.听Mandelblatt,聽MD, MPH; Donald A.听Berry,聽PhD; Allison W.听Kurian,聽MD, MSc; Sylvia K.听Plevritis,聽PhD
is active quiz
JAMA. 2024; 331(3):233-241. 10.1001/jama.2023.25881
This simulation study estimates the association of breast cancer screening, treatment of stage I-III breast cancer, and treatment of metastatic breast cancer on changes in mortality due to breast cancer in US women for the period 1975-2019.
JAMA
Research Letter
March 10, 2020
Allison W.听Kurian,聽MD, MSc; Ryan聽Bernhisel,聽MStat; Katie聽Larson,聽MS; Jennifer L.听Caswell-Jin,聽MD; Aladdin H.听Shadyab,聽PhD; Heather聽Ochs-Balcom,聽PhD; Marcia L.听Stefanick,聽PhD
free access
JAMA. 2020; 323(10):995-997. 10.1001/jama.2020.0229
This study uses Women鈥檚 Health Initiative data to compare the prevalence of pathogenic variants (PVs) in breast cancer susceptibility genes in postmenopausal women with vs without breast cancer to guide decisions about who should undergo PV testing.